Clinical Characteristics and Outcomes of Breakthrough Candidemia in 71 Hematologic Malignancy Patients and/or Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Single-center Retrospective Study From China, 2011–2018
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: Antifungal prophylaxis may result in breakthrough infections in hematology patients with severe agranulocytosis, with few studies assessing risk factors and clinical outcomes of breakthrough candidemia. We described the distribution of Candida species, assessed risk factors for mortality in such patients, and determined differences in the incidence and mortality of breakthrough candidemia between patients who did or did not receive an allogeneic hematopoietic stem cell transplant. Methods: We collected clinical and microbiological data of patients with hematologic malignancies and breakthrough candidemia from a single center. Seven-day and 30-day follow-up outcomes were recorded; the incidence and mortality of breakthrough candidemia between patients who did or did not undergo an allogeneic transplant were compared. Kaplan-Meier survival estimates were used to generate survival curves, and predictors were identified using Cox regression analyses. Results: Of 71 enrolled patients, 17 received allogeneic transplants. Incidences of breakthrough candidemia were 17 of 2924 (0.58%) and 54 of 12 015 (0.45%) in the transplant and nontransplant groups, respectively (P = .35). The most common isolate was Candida tropicalis, and antifungal agent combinations were the most common first-line treatment. Cumulative mortality rates of patients were 21.1% and 31.0% at days 7 and 30, respectively, and they significantly differed between both groups. Septic shock, central venous catheter removal, and granulocyte recovery were significantly associated with 7-day mortality; the latter 2 remained independent predictors of 30-day mortality. Conclusions: Breakthrough candidemia-related mortality was higher in the allogeneic transplant group, although the incidence was not significantly different between the groups. Prompt and adequate antifungal treatment with catheter removal may reduce mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but there are also ample reports of individuals who experienced breakthrough infections while receiving an echinocandins.97,98”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [97]
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12360 · Cited by 529
Tortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509
Segal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky‐Zeichner, L., Sobel, J., Viscoli, C., Walsh, T. J., Maertens, J., Patterson, T. F., Perfect, J. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590566 · Cited by 468
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Sipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269
Nucci, M., Anaissie, E., Betts, R. F., Dupont, B. F., Wu, C., Buell, D. N., Kovanda, L., & Lortholary, O. (2010) · Clinical Infectious Diseases · doi:10.1086/653935 · Cited by 228
Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection
Ben-Ami, R., Olshtain-Pops, K., Krieger, M., Oren, I., Bishara, J., Dan, M., Wiener-Well, Y., Weinberger, M., Zimhony, O., Chowers, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05947-11 · Cited by 178
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death
Slavin, M. A., Sorrell, T. C., Marriott, D., Thursky, K. A., Nguyen, Q., Ellis, D. H., Morrissey, C. O., Chen, S. C. A., & on behalf of the Australian Candidemia Study, A. S. F. I. D. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq053 · Cited by 162
Chitasombat, M. N., Kofteridis, D. P., Jiang, Y., Tarrand, J., Lewis, R. E., & Kontoyiannis, D. P. (2012) · Journal of Infection · doi:10.1016/j.jinf.2011.11.002 · Cited by 152
Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough Candidemia
Uzun, O., Ascioglu, S., Anaissie, E. J., & Rex, J. H. (2001) · Clinical Infectious Diseases · doi:10.1086/320757 · Cited by 138
The risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos-Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 134
Up to date epidemiology, diagnosis and management of invasive fungal infections
Oren, I., & Paul, M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12642 · Cited by 115
Gamaletsou, M. N., Walsh, T. J., Zaoutis, T., Pagoni, M., Kotsopoulou, M., Voulgarelis, M., Panayiotidis, P., Vassilakopoulos, T., Angelopoulou, M. K., Marangos, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12312 · Cited by 112
Corzo‐León, D. E., Satlin, M. J., Soave, R., Shore, T. B., Schuetz, A. N., Jacobs, S. E., & Walsh, T. J. (2015) · Mycoses · doi:10.1111/myc.12318 · Cited by 112
The Cava Trem Study Group, León, C., Ruiz-Santana, S., Saavedra, P., Castro, C., Loza, A., Zakariya, I., Úbeda, A., Parra, M., Macías, D., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1324-3 · Cited by 110
Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences
Clancy, C., & Nguyen, M. H. (2018) · Journal of Fungi · doi:10.3390/jof4010027 · Cited by 95
Puig‐Asensio, M., Ruíz-Camps, I., Fernández‐Ruiz, M., Aguado, J. M., Muñóz, P., Valerio, M., Delgado‐Iribarren, A., Merino, P., Bereciartúa, E., Fortün, J., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.12.027 · Cited by 82
Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections
Kim, S.-H., Yoon, Y. K., Kim, M. J., & Sohn, J. W. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03906.x · Cited by 67
Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucan
Nucci, M., Nouér, S. A., Esteves, P., Guimarães, T., Breda, G., de Miranda, B. G., Queiroz-Telles, F., & Colombo, A. L. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw188 · Cited by 67
Dewan, E., Biswas, D., Kakati, B., Verma, S., Kotwal, A., & Oberoi, A. (2015) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2015.06.006 · Cited by 35
Myoken, Y., Kyo, T., Fujihara, M., Sugata, T., & Mikami, Y. (2004) · PubMed · Cited by 31
Guitard, J., Isnard, F., Tabone, M., Antignac, M., Brissot, É., Senghor, Y., Petit, A., Leverger, G., & Hennequin, C. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.01.011 · Cited by 26
Kim, S.-H., Choi, J.-K., Cho, S.-Y., Lee, H.-J., Park, S. H., Choi, S.-M., Lee, D.-G., Choi, J.-H., Yoo, J.-H., & Lee, J.-W. (2018) · Medical Mycology · doi:10.1093/mmy/myx038 · Cited by 24
Gamaletsou, M. N., Daikos, G. L., Walsh, T. J., Perlin, D. S., Jiménez‐Ortigosa, C., Psaroulaki, A., Pagoni, M. N., Argyrοpoulou, A., Nepka, M., Perivolioti, E., et al. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.05.015 · Cited by 23
Uncommon yeast infections in hematological patients: from diagnosis to treatment
Caira, M., Trecarichi, E. M., Tumbarello, M., Leone, G. G. M., & Pagano, L. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.124 · Cited by 21
Myoken, Y., Kyo, T., Sugata, T., Murayama, S. Y., & Mikami, Y. (2006) · PubMed · Cited by 16
Cited by
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“97,98 Outcomes If recognized early and managed appropriately, most BT Candida infections can be treated successfully with antifungal therapy including optimization of dosing, source control, and recognizing potential drug-drug interactions.”
BackgroundStrategies to Prevent Transmission of Candida auris in Healthcare Settings
Ahmad, S., & Asadzadeh, M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00451-7 · Cited by 77
Asadzadeh, M., Mokaddas, E., Ahmad, S., Abdullah, A. A., de Groot, T., Meis, J. F., & Shetty, S. A. (2022) · Mycoses · doi:10.1111/myc.13419 · Cited by 55
Liu, F., Zhong, L., Zhou, F., Zheng, C., Zhang, K., Cai, J., Zhou, H., Tang, K., Dong, Z., Cui, W., et al. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s323583 · Cited by 41
Al-Obaid, I., Asadzadeh, M., Ahmad, S., Alobaid, K., Alfouzan, W., Bafna, R., Emara, M., & Joseph, L. (2022) · Journal of Fungi · doi:10.3390/jof8030267 · Cited by 39
Metadata
- Authors
- Chen, X.-C., Xu, J., & Wu, D.-P.
- Affiliations
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
- First Affiliated Hospital of Soochow University (CN)
- ORCID
- Xu, Jie
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-15
- Volume
- 71
- Issue
- Supplement_4
- Pages
- S394-S399
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3117569217
- Cited by
- 32
- References
- 31
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 3
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81730003)
- National Science and Technology Major Project (2017ZX09304021)
- National Key Research and Development Program of China
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- Candida tropicalis, hematologic malignancies, allogeneic hematopoietic stem cell transplantation, antifungal prophylaxis, antifungal therapy, mortality risk factors, septic shock, central venous catheter removal, granulocyte recovery, agranulocytosis, Candida species distribution
- MeSH terms
- Antifungal Agents, China, Humans, Retrospective Studies, Risk Factors, Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.